{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Diab A"],"funding":["Pfizer"],"pagination":["71-83"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9401502"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(1)"],"pubmed_abstract":["<h4>Purpose</h4>Stimulation of effector T cells is an appealing immunotherapeutic approach in oncology. OX40 (CD134) is a costimulatory receptor expressed on activated CD4<sup>+</sup> and CD8<sup>+</sup> T cells. Induction of OX40 following antigen recognition results in enhanced T-cell activation, proliferation, and survival, and OX40 targeting shows therapeutic efficacy in preclinical studies. We report the monotherapy dose-escalation portion of a multicenter, phase I trial (NCT02315066) of ivuxolimab (PF-04518600), a fully human immunoglobulin G2 agonistic monoclonal antibody specific for human OX40.<h4>Patients and methods</h4>Adult patients (<i>N</i> = 52) with selected locally advanced or metastatic cancers received ivuxolimab 0.01 to 10 mg/kg. Primary endpoints were safety and toler"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers."],"pmcid":["PMC9401502"],"funding_grant_id":["NCT02315066"],"pubmed_authors":["Doi T","Hamid O","Klempner SJ","Salek-Ardakani S","Eskens FALM","Ganguly B","Thompson JA","Joh T","Liao K","Chou J","Diab A","Fleener C","El-Khoueiry AB","Ros W","Taylor CT","Wang X","Hu-Lieskovan S"],"additional_accession":[]},"is_claimable":false,"name":"A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers.","description":"<h4>Purpose</h4>Stimulation of effector T cells is an appealing immunotherapeutic approach in oncology. OX40 (CD134) is a costimulatory receptor expressed on activated CD4<sup>+</sup> and CD8<sup>+</sup> T cells. Induction of OX40 following antigen recognition results in enhanced T-cell activation, proliferation, and survival, and OX40 targeting shows therapeutic efficacy in preclinical studies. We report the monotherapy dose-escalation portion of a multicenter, phase I trial (NCT02315066) of ivuxolimab (PF-04518600), a fully human immunoglobulin G2 agonistic monoclonal antibody specific for human OX40.<h4>Patients and methods</h4>Adult patients (<i>N</i> = 52) with selected locally advanced or metastatic cancers received ivuxolimab 0.01 to 10 mg/kg. Primary endpoints were safety and toler","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2026-05-28T03:45:58.74Z","creation":"2025-04-06T00:51:47.491Z"},"accession":"S-EPMC9401502","cross_references":{"pubmed":["34615725"],"doi":["10.1158/1078-0432.CCR-21-0845"]}}